Therapy of primary amyloidosis with melphalan and prednisone
Authors:
- Richard S. SchwartzRSRichard S. Schwartz
- James R. CohenJCJames R. Cohen
- Stanley L. SchrierSSStanley L. Schrier
- 1 October 1979
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 139 (10) , 1144-1147
Abstract
Two patients with progressive primary amyloidosis, monoclonal serum and urinary proteins, multiple organ involvement, and nephrotic syndrome were treated with melphalan and prednisone for one year. In one patient, splenomegaly and nephrotic syndrome rapidly responded to therapy but massive hepatomegaly responded slowly, requiring 15 months' time for normalization of size. Results of liver function tests, although improved, remained abnormal, and amyloid deposits remained in the marrow. A second patient also demonstrated dramatic diminution in proteinuria and improvement in liver function abnormalities, but macroglossia persisted. These observations suggest that amyloid organ involvement may be reversible with differences in organ responsiveness to chemotherapy. An empirical trial of chemotherapy may be indicated in some patients with progressive primary amyloidosis, and therapy may need to be continued for a prolonged period of time before seeing an effect. (Arch Intern Med139:1144-1147, 1979)Keywords
This publication has 8 references indexed in Scilit:
- PRIMARY SYSTEMIC AMYLOIDOSIS - COMPARISON OF MELPHALAN AND PREDNISONE VERSUS PLACEBO1978
- Prolonged Colchicine Treatment in Four Patients with AmyloidosisAnnals of Internal Medicine, 1977
- Improvement in AmyloidosisAnnals of Internal Medicine, 1975
- Resolution of Primary Amyloidosis During ChemotherapyAnnals of Internal Medicine, 1975
- Melphalan Therapy for Plasma Cell MyelomaBlood, 1968
- AmyloidosisNew England Journal of Medicine, 1967
- AmyloidosisNew England Journal of Medicine, 1967
- AmyloidosisNew England Journal of Medicine, 1967